Developing innovative treatments to multiple diseases based on a proprietary approach to furin inhibition.

UNWANTED IMMUNE RESPONSES - The immune system is the body's defense against infections and other foreign invaders. However, thousands of patients suffer every day due to immune system malfunctions. Some patients suffer because their immune system “attacks” their own healthy cells as a foreign invader. Other patients suffer because their prescribed therapies are “attacked” by the immune system as a foreign invader. As a result, billions of healthcare dollars are expended due to these failures.PLATFORM TECHNOLOGY - ZOETIC Pharmaceuticals is an early stage company advancing proprietary technology that directly addresses and corrects the harmful immune responses that: 1) are directly responsible for initiation and progression of autoimmune disease, 2) adversely affect the safety and performance of bio-therapeutics, and 3) prevent the successful delivery of viral vector mediated gene therapy.

Launch NY is a non-profit venture development organization that provides managerial guidance and financial support to high growth entrepreneurial companies across 27 counties in upstate New York.

The Independent Drug Information Service (IDIS) is an innovative program designed to provide physicians with an evidence-based, non-commercial source of the latest findings about the drugs they prescribe.

Full operational responsibility for pre-clinical contract research organization, spun out from the Medical College of Wisconsin. Specific accomplishments include:• 50% growth in revenue for 2005 versus 2004• Three fold expansion of active client list• Secured $1.5M in second round financingFull operational and financial responsibility for privately held organization providing contract support services to the pharmaceutical industry. Within first six months, reorganized into customer focused operational business units, and grew revenue by 38%. Specific accomplishments include:• Increased revenue from $3.5M to $8M in three-year period• Instituted management training and grew operational staff from 40 to 80• Positioned the company for sale, and secured three offers for acquisition

Responsible for all daily operational issues of a technology based contract research organization providing innovative services to the pharmaceutical and biotechnology industries. General management role included sales, marketing, operations and new product development. Specific accomplishments include:• Successfully completed three rounds of private financing over a three-year period, securing over $10M in investment capital• Established European operations which were critical for securing over 40% of 1998 sales, and positioning AVANTEC as an international provider of services• Sales grew over 300% in first six months of 1998 to $6M, resulting in a 100% growth in monthly revenue

Responsible all aspects of international marketing for contract research services, including the refinement of pricing policies and the development of the launch campaign for European expansion. Through a detailed analysis of the current product mix, significantly increased operating margins by moving customers towards more profitable projects. Specific accomplishments include:• Grew revenue to over $20M, from $12M, in a two-year period• Developed strategic pricing which grew operating margin over 15%Responsible for a portfolio of eight biotechnology products in various stages of pre-clinical and clinical development valued at over $500M. Managed financial forecasts, licensing strategies, franchise marketing and initial new product launch campaigns. Secured a positive identity for Ortho Biotech within an established imaging market by focusing on the explosive opportunity offered through biotechnology products and the long-term commitment of the organization.Responsible for growing annual product sales to $100M in a highly competitive and price sensitive market by leveraging opinion leaders and focusing on educational support programs. .